title: Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
abstract: Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials.
authors.affiliation: a Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Khawla F
authors.initials: KF
authors.lastname: Ali
authors.affiliation: a Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Alpana P
authors.initials: AP
authors.lastname: Shukla
authors.affiliation: a Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism , Weill Cornell Medical College , New York , NY , USA.
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Aronne
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D017277:Drug Approval; D004338:Drug Combinations; D006801:Humans; D009271:Naltrexone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; C000591595:bupropion hydrochloride, naltrexone hydrochoride drug combination; D016642:Bupropion; D009271:Naltrexone
keywords: Naltrexone; bupropion; obesity; type 2 diabetes; weight loss